Davidson Investment Advisors Sells 15,902 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Davidson Investment Advisors reduced its Bristol Myers Squibb stake by 5.4%, selling 15,902 shares and retaining 277,201 shares valued at approximately $15.97 million. Institutional investors collectively own 76.41% of BMY.
• Bristol Myers Squibb reported quarterly EPS of $2.04, exceeding the $1.60 consensus estimate, while revenue rose 5.7% year over year to $12.97 billion. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $66.06.
• The company’s outlook includes potential growth from FDA-approved Zenbexus and continued pipeline investments, but competition for Camzyos and manufacturing setbacks involving Breyanzi create risks. BMY also offers a quarterly dividend of $0.63 per share, representing a 3.8% annualized yield.

Davidson Investment Advisors reduced its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 5.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 277,201 shares of the biopharmaceutical company's stock after selling 15,902 shares during the quarter. Davidson Investment Advisors' holdings in Bristol Myers Squibb were worth $15,972,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of BMY. Swiss RE Ltd. bought a new position in shares of Bristol Myers Squibb in the 4th quarter worth $25,000. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth $25,000. Davis Asset Management L.P. purchased a new position in Bristol Myers Squibb in the second quarter worth $27,000. Bayban bought a new position in Bristol Myers Squibb in the fourth quarter valued at $31,000. Finally, Addison Advisors LLC bought a new position in Bristol Myers Squibb in the second quarter valued at $32,000. 76.41% of the stock is currently owned by institutional investors.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA approved Zenbexus (iberdomide), an oral therapy for adults with relapsed or refractory multiple myeloma when used with Johnson & Johnson’s Darzalex and dexamethasone. As the first approved CELMoD therapy in this setting, Zenbexus provides BMY with another potential oncology growth driver and may help diversify its product portfolio. Will ZENBEXUS’s First-in-Class CELMoD Approval Based on MRD-Negative CR Change Bristol Myers Squibb’s Narrative?
• Positive Sentiment: BMY paid Atrium Therapeutics a $15 million milestone after Atrium delivered a lead RNA compound for an undisclosed cardiovascular indication. The payment signals progress in the collaboration and could strengthen investor confidence in BMY’s cardiovascular research pipeline, although the program remains early-stage and details are limited. Can Atrium Therapeutics’ $15 Million Milestone From Bristol-Myers Squibb Validate its RNA Platform?
• Neutral Sentiment: BMY announced a follow-on study for its deucravacitinib program, indicating continued investment in autoimmune diseases. The update supports the company’s longer-term pipeline strategy but does not yet provide a near-term revenue catalyst. Bristol-Myers Squibb Extends Deucravacitinib Program
• Negative Sentiment: Cytokinetics reported a first-ever Phase 3 success in non-obstructive hypertrophic cardiomyopathy, intensifying competition with BMY’s Camzyos cardiovascular franchise. A successful rival could pressure Camzyos’ longer-term growth prospects. Cytokinetics Scores a First-Ever in Its Rivalry Against Bristol Myers
• Negative Sentiment: BMY ended its partnership with Cellares after determining that the company’s manufacturing platform could not produce Breyanzi at commercial scale. The decision may delay planned capacity expansion for the cell therapy and raises questions about Breyanzi’s ability to meet future demand. Bristol-Myers Squibb’s Cellares Exit Raises Questions Over Breyanzi Growth
• Negative Sentiment: SVP Phil Holzer sold 500 BMY shares for approximately $33,750. The relatively small transaction is unlikely to materially affect fundamentals, but it adds a modest negative signal. Bristol Myers Squibb SVP Phil Holzer Sells 500 Shares

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the company's stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares of the company's stock, valued at $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.05% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

BMY has been the subject of several research analyst reports. TD Cowen began coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a "buy" rating for the company. Piper Sandler began coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set an "overweight" rating on the stock. Raymond James Financial started coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a "strong-buy" rating for the company. Truist Financial reaffirmed a "buy" rating and issued a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Finally, JPMorgan Chase & Co. increased their price target on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an "overweight" rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $66.06.

Bristol Myers Squibb Stock Down 0.5%

Shares of NYSE BMY opened at $66.62 on Friday. The firm's fifty day moving average is $61.76 and its 200 day moving average is $59.68. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The company has a market cap of $136.09 billion, a price-to-earnings ratio of 14.67, a PEG ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company's revenue was up 5.7% on a year-over-year basis. During the same quarter last year, the firm earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities research analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.8%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb's payout ratio is currently 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source